Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor... see more

Recent & Breaking News (NDAQ:MGNX)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

Accesswire September 15, 2024

MGNX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against MacroGenics, Inc.

Accesswire September 15, 2024

MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

Accesswire September 15, 2024

MacroGenics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Accesswire September 15, 2024

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 15, 2024

MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 15, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Newsfile September 15, 2024

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

GlobeNewswire September 15, 2024

MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

Accesswire September 14, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action - MGNX

Newsfile September 14, 2024

MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Newsfile September 14, 2024

The Schall Law Firm Invites Investors To Participate In A Securities Fraud Case Against MacroGenics, Inc.

Accesswire September 14, 2024

MacroGenics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

Accesswire September 14, 2024

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action - MGNX

Newsfile September 13, 2024

Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class Action - MGNX

Accesswire September 13, 2024

MacroGenics (MGNX) Investors with Substantial Losses Encouraged to Contact Hagens Berman Before September 24th Deadline in Securities Class Action

Accesswire September 13, 2024

Lost Money on MacroGenics, Inc. (MGNX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire September 13, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

Accesswire September 13, 2024

Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

Accesswire September 13, 2024

MacroGenics Inc Is Being Sued For Securities Law Violations And Shareholders Are Urged To Contact The Schall Law Firm

Accesswire September 13, 2024